Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

1.0K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.0K
Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

5.7K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
5.7K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

938
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
938
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

1.1K
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.1K
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

1.8K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
1.8K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

673
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
673

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chest wall heterotopic ossification causing restrictive physiology after resuscitative thoracotomy and surgical stabilization of rib fractures: a report and review.

Trauma surgery & acute care open·2026
Same author

The effect of additional skin wetting on physiological strain and exercise performance: systematic review and meta-analysis.

Journal of thermal biology·2026
Same author

From healthy to heart failure in 24 hours: defining the upper limit of exercise-induced cardiac fatigue.

Journal of applied physiology (Bethesda, Md. : 1985)·2026
Same author

The Measurement and Application of Critical Speed and D' in Running: A Scoping Review.

Sports medicine (Auckland, N.Z.)·2026
Same author

Traumatic brain injury (TBI) triage tool for low-risk patients: standardizing TBI care at a Level 1 trauma center.

Trauma surgery & acute care open·2025
Same author

The implementation of an electronic symptom management system to monitor postoperative pain in thoracic surgery patients: A multicenter evaluation.

JTCVS open·2025

Related Experiment Video

Updated: Nov 23, 2025

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

1.5K

Novel Tocolytic Strategy: Modulating Cx43 Activity by S-Nitrosation.

Scott D Barnett1, Hazik Asif2, Mitchell Anderson2

  • 1Department of Pharmacology, Myometrial Function Group, University of Nevada, Reno School of Medicine, Reno, NV sdbarnett@med.unr.edu.

The Journal of Pharmacology and Experimental Therapeutics
|January 1, 2021
PubMed
Summary

Spontaneous preterm labor involves dysregulated connexin-43 (Cx43). Inhibiting Cx43 and its S-nitrosation with 18β-glycyrrhetinic acid and nebivolol effectively reduces myometrial contractions, offering a novel treatment for preterm birth.

More Related Videos

Perturbing Endothelial Biomechanics via Connexin 43 Structural Disruption
09:20

Perturbing Endothelial Biomechanics via Connexin 43 Structural Disruption

Published on: October 4, 2019

5.8K
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

25.9K

Related Experiment Videos

Last Updated: Nov 23, 2025

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

1.5K
Perturbing Endothelial Biomechanics via Connexin 43 Structural Disruption
09:20

Perturbing Endothelial Biomechanics via Connexin 43 Structural Disruption

Published on: October 4, 2019

5.8K
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

25.9K

Area of Science:

  • Reproductive biology
  • Pharmacology
  • Cellular signaling

Background:

  • Current tocolytics are largely ineffective for delaying preterm birth.
  • Understanding the mechanisms of spontaneous preterm labor (sPTL) is crucial for developing new treatments.
  • Nitric oxide (NO)-mediated protein S-nitrosation (SNO) is key to myometrial relaxation, not cyclic nucleotides.

Purpose of the Study:

  • To investigate the role of connexin-43 (Cx43) in spontaneous preterm labor (sPTL).
  • To determine if Cx43 S-nitrosation by NO influences myometrial contractility.
  • To evaluate the potential of Cx43 inhibition and NO-mediated SNO as a novel tocolytic strategy.

Main Methods:

  • Protein analysis of human myometrium from sPTL cases.
  • Assessment of Cx43 S-nitrosation and phosphorylation.
  • Pharmacologic inhibition of Cx43 using 18β-glycyrrhetinic acid (18β-GA).
  • Activation of NO synthase with nebivolol.
  • Evaluation of contractile dynamics in myometrial tissue.

Main Results:

  • Cx43 is downregulated in sPTL myometrium.
  • NO-mediated S-nitrosation of Cx43 correlates with increased Cx43 phosphorylation (inhibiting gap junctions) and increased hemichannel (HC) open-state probability (promoting quiescence).
  • Pharmacologic inhibition of Cx43 with 18β-GA and NO synthase activation with nebivolol individually reduced myometrial contractility.
  • Co-administration of 18β-GA and nebivolol additively reduced contractions, nearly eliminating them.

Conclusions:

  • Cx43 is a critical contractile-associated protein dysregulated in sPTL.
  • NO-mediated S-nitrosation of Cx43 plays a significant role in myometrial quiescence.
  • Targeting Cx43 and its S-nitrosation with 18β-GA and nebivolol presents a novel therapeutic approach for sPTL.